Cargando…
The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice
Pharmacokinetic exposures to fexofenadine (FEX) are reduced by apple juice (AJ); however, the relationship between the AJ volume and the degree of AJ‐FEX interaction has not been understood. In this crossover study, 10 healthy subjects received single doses of FEX 60 mg with different volumes (150,...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351340/ https://www.ncbi.nlm.nih.gov/pubmed/27197662 http://dx.doi.org/10.1111/cts.12400 |
_version_ | 1782514757804228608 |
---|---|
author | Luo, J Imai, H Ohyama, T Hashimoto, S Hasunuma, T Inoue, Y Kotegawa, T Ohashi, K Uemura, N |
author_facet | Luo, J Imai, H Ohyama, T Hashimoto, S Hasunuma, T Inoue, Y Kotegawa, T Ohashi, K Uemura, N |
author_sort | Luo, J |
collection | PubMed |
description | Pharmacokinetic exposures to fexofenadine (FEX) are reduced by apple juice (AJ); however, the relationship between the AJ volume and the degree of AJ‐FEX interaction has not been understood. In this crossover study, 10 healthy subjects received single doses of FEX 60 mg with different volumes (150, 300, and 600 mL) of AJ or water (control). To identify an AJ volume lacking clinically meaningful interaction, we tested a hypothesis that the 90% confidence interval (CI) for geometric mean ratio (GMR) of FEX AUC(AJ)/AUC(water) is contained within a biocomparability bound of 0.5–2.0, with at least one tested volume of AJ. GMR (90% CI) of AUC(AJ 150mL)/AUC(water), AUC(AJ 300mL)/AUC(water), and AUC(AJ 600mL)/AUC(water) were 0.903 (0.752–1.085), 0.593 (0.494–0.712), and 0.385 (0.321–0.462), respectively. While a moderate to large AJ‐FEX interaction is caused by a larger volumes of AJ (e.g., 300 to 600 mL), the effect of a small volume (e.g., 150 mL) appears to be not meaningful. |
format | Online Article Text |
id | pubmed-5351340 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-53513402017-05-23 The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice Luo, J Imai, H Ohyama, T Hashimoto, S Hasunuma, T Inoue, Y Kotegawa, T Ohashi, K Uemura, N Clin Transl Sci Research Pharmacokinetic exposures to fexofenadine (FEX) are reduced by apple juice (AJ); however, the relationship between the AJ volume and the degree of AJ‐FEX interaction has not been understood. In this crossover study, 10 healthy subjects received single doses of FEX 60 mg with different volumes (150, 300, and 600 mL) of AJ or water (control). To identify an AJ volume lacking clinically meaningful interaction, we tested a hypothesis that the 90% confidence interval (CI) for geometric mean ratio (GMR) of FEX AUC(AJ)/AUC(water) is contained within a biocomparability bound of 0.5–2.0, with at least one tested volume of AJ. GMR (90% CI) of AUC(AJ 150mL)/AUC(water), AUC(AJ 300mL)/AUC(water), and AUC(AJ 600mL)/AUC(water) were 0.903 (0.752–1.085), 0.593 (0.494–0.712), and 0.385 (0.321–0.462), respectively. While a moderate to large AJ‐FEX interaction is caused by a larger volumes of AJ (e.g., 300 to 600 mL), the effect of a small volume (e.g., 150 mL) appears to be not meaningful. John Wiley and Sons Inc. 2016-05-19 2016-08 /pmc/articles/PMC5351340/ /pubmed/27197662 http://dx.doi.org/10.1111/cts.12400 Text en © 2016 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Luo, J Imai, H Ohyama, T Hashimoto, S Hasunuma, T Inoue, Y Kotegawa, T Ohashi, K Uemura, N The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice |
title | The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice |
title_full | The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice |
title_fullStr | The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice |
title_full_unstemmed | The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice |
title_short | The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice |
title_sort | pharmacokinetic exposure to fexofenadine is volume‐dependently reduced in healthy subjects following oral administration with apple juice |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351340/ https://www.ncbi.nlm.nih.gov/pubmed/27197662 http://dx.doi.org/10.1111/cts.12400 |
work_keys_str_mv | AT luoj thepharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice AT imaih thepharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice AT ohyamat thepharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice AT hashimotos thepharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice AT hasunumat thepharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice AT inouey thepharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice AT kotegawat thepharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice AT ohashik thepharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice AT uemuran thepharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice AT luoj pharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice AT imaih pharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice AT ohyamat pharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice AT hashimotos pharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice AT hasunumat pharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice AT inouey pharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice AT kotegawat pharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice AT ohashik pharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice AT uemuran pharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice |